2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethanone
C25H22ClF3N6O — CID 66575936
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethanone
2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethanone (PubChem CID 66575936) has the molecular formula C25H22ClF3N6O and a molecular weight of 514.94 g/mol. Its IUPAC name is 2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethanone.
Molecular Properties
| Compound Name | 2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethanone |
|---|---|
| PubChem CID | 66575936 |
| Molecular Formula | C25H22ClF3N6O |
| Molecular Weight | 514.94 g/mol |
| Exact Mass | 514.15 |
| IUPAC Name | 2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethanone |
| SMILES | O=C(Cn1nc(-c2ccccc2)c2c(Cl)c(-c3ccccc3)nnc21)N1CCN(CC(F)(F)F)CC1 |
| InChI | InChI=1S/C25H22ClF3N6O/c26-21-20-22(17-7-3-1-4-8-17)32-35(24(20)31-30-23(21)18-9-5-2-6-10-18)15-19(36)34-13-11-33(12-14-34)16-25(27,28)29/h1-10H,11-16H2 |
| InChIKey | CFCNKCPTKNCNTM-UHFFFAOYSA-N |
| XLogP | 4.52 |
| TPSA | 67.15 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 514.94 |
| LogP ≤ 5 | 4.52 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 66575936 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.